Other members of the senior management team are Marlene Modi, Ph.D., former Senior Director at Eyetech and Hoffmann-La Roche, who is Vice President, Preclinical Development; Manju Patel, M.D., former Senior Director and Development Leader for Retina Strategy at Pfizer Inc., who is the Chief Medical Officer; and Haren Vasavada, Ph.D., former Director in the Department of Research Technologies at Bayer, who is Vice President, Process Sciences.
Optherion was founded by Scheer & Company, Dr. Hageman, and Sandy Gordon, M.D., an ophthalmologist with extensive ophthalmic and venture capital experience. Scheer & Company was responsible for managing Optherion's operations in the formative stage. Scheer & Company was also involved in the founding of ViroPharma, OraPharma (now a unit of Johnson & Johnson), Esperion Therapeutics (now a unit of Pfizer Global Research & Development Division), Achillion Pharmaceuticals, Sopherion Therapeutics, Aegerion Pharmaceuticals, and Tengion.
"The successful completion of this Series A financing will enable the company to advance the work of Dr. Hageman, Dr. Hoh and others, and hopefully transform the diagnosis and treatment of dry age-related macular degeneration," said David Scheer, Chairman of the Optherion Board of Directors.
Joining Mr. Scheer on the Board of Directors are Sherrill Neff (Quaker), Brian Halak, Ph.D.(Domain), Mr. Foster, and Ginger More, formerly General Partner at Oak Investment Partners, as an independent director.
Mr. Neff said: "We are enthused to be investing in Optherion. This presents an opportunity for us to change the treatment and diagnosis of a disease that affects the lives of millions of people."
|SOURCE Optherion, Inc.|
Copyright©2007 PR Newswire.
All rights reserved